US Patent

US11975013 — Stable formulations comprising thiotepa

Formulation · Assigned to Shorla Pharma Ltd · Expires 2041-08-16 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable pharmaceutical compositions of thiotepa that include PEG, DMSO, and optionally water or an aqueous saline solution and thiosulfate.

USPTO Abstract

The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.

Drugs covered by this patent

Patent Metadata

Patent number
US11975013
Jurisdiction
US
Classification
Formulation
Expires
2041-08-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Shorla Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.